{
    "organizations": [],
    "uuid": "27213c10b608c6617cd24385894e8dbfcb55e3a3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-approves-addition-of-overall-s/brief-fda-approves-addition-of-overall-survival-data-to-kyprolis-label-idUSASB0C1BF",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - Amgen Inc:\n* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLISÂ® (CARFILZOMIB) LABEL\n* AMGEN INC - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-18T05:43:00.000+02:00",
    "crawled": "2018-01-18T16:26:21.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "amgen",
        "inc",
        "fda",
        "approves",
        "addition",
        "overall",
        "survival",
        "data",
        "carfilzomib",
        "label",
        "amgen",
        "inc",
        "fda",
        "approved",
        "supplemental",
        "new",
        "drug",
        "application",
        "add",
        "overall",
        "survival",
        "data",
        "phase",
        "trial",
        "prescribing",
        "information",
        "kyprolis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}